Denali Therapeutics Inc. — Director's Dealing 2018

Mar 1, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2017-12-13

Reporting Person: Watts Ryan J. (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-13	Common Stock	A	5	$20.47	Acquired	12505	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-02-26	Stock Option (right to buy)	$22.16	A	300000	Acquired	2028-02-25	Common Stock (300000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2802638	Indirect

Footnotes

F1: The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.

F2: 25% of the shares subject to the option will vest on February 26, 2019 and an additional 1/48 of the shares vest monthly thereafter.